These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24196074)

  • 1. [Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].
    Ema T; Kawano R; Enomoto Y
    Gan To Kagaku Ryoho; 2013 Oct; 40(10):1377-80. PubMed ID: 24196074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
    Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
    Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
    Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
    Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
    Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
    Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
    Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
    Tanaka H; Okamoto T; Shinyama M; Matsumura S; Fujii T
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):1067-9. PubMed ID: 23986053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
    Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
    Drpa G; Sreter KB; Manojlovic S; Kukulj S
    Anticancer Drugs; 2018 Mar; 29(3):281-285. PubMed ID: 29280916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
    Katono K; Kasajima M; Ishihara M; Hayashi N; Nagashima Y; Igawa S; Masuda N
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):375-7. PubMed ID: 23507602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
    Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
    Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
    Hellmann MD; Reva B; Yu H; Rusch VW; Rizvi NA; Kris MG; Arcila ME
    J Thorac Oncol; 2014 Oct; 9(10):e73-4. PubMed ID: 25521405
    [No Abstract]   [Full Text] [Related]  

  • 14. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
    Yang JC; Hirsh V; Schuler M; Yamamoto N; O'Byrne KJ; Mok TS; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist LV
    J Clin Oncol; 2013 Sep; 31(27):3342-50. PubMed ID: 23816967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
    Chen WQ; Li P; Wang Q; Zhang YJ; Li HY; Jin XT; Yan S; Kou GF; Cai SL; Liu G
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):133-137. PubMed ID: 29502374
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Aug; 33(8):3397-402. PubMed ID: 23898110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.
    Kumar R; Dubashi B; Kayal S; Lazzar SC; Barathi D; Kumar V
    Indian J Cancer; 2017; 54(1):188-192. PubMed ID: 29199688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.